Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 66 for “"Spironolactone"”.
-
The Effect of Spironolactone on Cerebral Blood Flow and Cognition
… the effects are potentially reversible by spironolactone (Spiro) reducing blood pressure (BP) and arterial stiffness. This thesis consisted of a double-blind, controlled trial with older hypertensive adults (OA) who were receiving stable treatment with centrally acting angiotensin …
-
Repurposing Spironolactone as a Survivin Targeting Therapeutic in Canine Osteosarcoma
… therapeutic target. This thesis investigated spironolactone, a mineralocorticoid receptor antagonist, as a repurposed anti-cancer and chemosensitizing agent in cOSA. Abrams and D17 cells were treated with spironolactone alone or combined with carboplatin, doxorubicin, paclitaxel, or …
-
The effect of spironolactone on cardiovascular disease in early stage chronic kidney disease
… the arteries, heart and kidney. Treatment with spironolactone, which blocks aldosterone at the mineralocorticoid receptor might be effective at reducing such injury. To address these hypotheses, I performed an observational study in patients with early stage CKD without known cardiovascular …
-
Spironolactone to treat hypertension in end-stage renal disease : analysis of effectiveness and safety
… from continued renal cellular damage⁸⁻¹⁰. Spironolactone, an aldosterone antagonist, has the potential to provoke hyperkalemia. Consequently, current guidelines do not recommend spironolactone to manage hypertension in ESRD because of this risk⁶⁻⁷. Our primary objectives were to determine …
-
The effect of spironolactone on exercise capacity in functionally impaired older people without heart failure
… of the renin-angiotensin-aldosterone system with spironolactone would improve physical function in older people without heart failure. In a double-blind, randomised controlled clinical trial 120 participants, aged >65 years with functional impairment were randomized to receive 25mg spironolactone …
-
ASSESSING POTENTIALLY INAPPROPRIATE MEDICATION USE IN PATIENTS AT RISK FOR ADVERSE DRUG EFFECTS: SPIRONOLACTONE AS A CASE STUDY
… patient kidney function. One such medication, spironolactone, an aldosterone antagonist indicated for heart failure, has been demonstrated in clinical trials to reduce morbidity and mortality among individuals with normal renal function, but its safety in those with chronic kidney disease (CKD) …
-
Phase II 6-month cyclic progesterone/spironolactone pilot therapy trial in polycystic ovary syndrome—a pre-post one-arm feasibility study
… a 6-month treatment with cyclic progesterone and spironolactone on health-related quality of life in women with androgenic PCOS. Methods: A 6-month open-label, pre-post pilot study was conducted with 26 participants (mean age 29 ± 4.9 years, BMI 30.3 ± 8.1 kg/m², 61.5% White). Within-woman changes …
-
Role of aldosterone in cardiac remodeling post-myocardial infarction and after high salt diet
… or high salt (8%) diet, either without or with spironolactone (20 or 80 mg/kg/day) were given to Wistar rats for 4 and 8 weeks. Both LV weight and cardiomyocyte cross-sectional diameter were increased significantly by high salt diet after 4 and 8 weeks. Both LV and right ventricle (RV) collagen …
-
Μελέτη της επίδρασης της σπιρονολακτόνης στη έκφραση γονιδίων που σχετίζονται με τη μυοκαρδιακή ίνωση σε υπερτασικούς επιίμυες
… of mineralocorticoid receptor – and specifically spironolactone - reduces cardiac fibrosis include the downregulation of mRNA expression of angiotensinogen converting enzyme, the reduction of aldosterone - induced collagen production by cardiac fibroblasts and the prevention of perivascular …
-
Mineralocorticoid receptor involvement in vascular dysfunction associated with vascular injury
… late-stage diabetes. MR inhibition with spironolactone treatment improved coronary endothelium-dependent vasodilation in OLETF rats. Further, RNA sequencing of aortas from Spironolactone-treated OLETF rats revealed 157 differentially expressed genes predicting MR involvement in …
-
Aldosterone-induced endothelial glycocalyx dysfunction, a potential therapeutic target in proteinuria?
… organ damage in heart failure and renal disease. Spironolactone, a mineralocorticoid receptor inhibitor, slows disease progression but side effects including hyperkalemia limit its use. Damage to the endothelial glycocalyx (a luminal biopolymer layer) has been implicated in pathogenesis of …
-
New drugs in prevention of experimental corneal graft rejection
… receptor agonist (SEGRA), everolimus and spironolactone on the prevention of allograft rejection in a MHC class I/II mismatch rat corneal transplant model. Methods: A total of 133 female Lewis rats underwent PKP. Syngeneic corneal grafting in 20 rats served as control for technical …
-
Paediatric drug development:reformulation, in vitro, genomic and in vivo evaluation
… and the potassium-sparing diuretic spironolactone was selected from the NHS specials list for November 2011 drug tariff with the view to produce oral liquid formulations providing dosage forms targeting paediatrics. Lisinopril, ramipril and spironolactone were chosen for their …
-
Mineralocorticoid-receptor antagonism and its metabolic consequences in haemodialysis patients
… was set up to investigate the effect of 50 mg of spironolactone once daily on left ventricular mass index in haemodialysis patients and several secondary endpoints. This dissertation reports findings from the MiREnDa trial on (a) the efficacy of spironolactone to influence serum levels of …
-
Monocyte subsets in atrial fibrillation with preserved left ventricular function
… 4) markers of cardiac fibrosis, 5) utility of Spironolactone to aid in improved exercise capacity in this cohort of patients. Methods: Monocyte subsets were analysed by flow cytometry on venous blood samples in 250 patients with permanent atrial fibrillation and preserved left ventricular …
-
Role of aldosterone and the aldosterone binding globulin in experimental and spontaneous hypertension
… by adrenalectomy or administration of a spironolactone but not by adrenalectomy when physiological amounts of aldosterone were concomitantly administered with ABG-TsU The elevated BP in rats treated with ABG-TsU for two weeks was due to increased cardiac output since total peripheral …
-
Electrolyte Metabolism During the Oestrous Cycle in the Rat
… rate was observed during the oestrous cycle. Spironolactone blocked the increased sodium and water retention and potassium excretion observed at oestrus, but had little effect on renal electrolyte function in dioestrous or ovariectomised animals. Spironolactone has been shown to inhibit the …
-
Endocrinology of equine metabolic pathophysiology
… the mineralocorticoid receptor antagonist spironolactone to pony mares. We found no change in cortisol or leptin concentrations between treatments, but did see a trend for increased aldosterone concentrations in the blood of spironolactone treated ponies over time. Further work is necessary …
-
Διερεύνηση της επίδρασης των κορτικοστεροειδών, του αγγειακού ενδοθηλιακού αυξητικού παράγοντα (VEGF) και αναστολέων τους στη διαπερατότητα του υπεζωκότα προβάτου
… Μ) and the mineralocorticoid receptor antagonist spironolactone (10-5 M) were used. In order to be studied some of the potential mechanisms of action of dexamethasone, EIPA (10-4 M), a specific inhibitor of the Na+ -H+ exchanger, amiloride (10-5 Μ), that inhibits Na+ channels and ouabain (10-4 Μ) …
Page 1 of 4